Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
NCT ID NCT04691570
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilirubin. Participants are adults with confirmed wAIHA and low hemoglobin levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ANX005
- What this could lead to
- If successful, ANX005 could offer a new treatment option for people with warm autoimmune hemolytic anemia, potentially improving red blood cell counts and reducing disease symptoms.
- What could go wrong
- This is a small, early-phase trial with only 7 participants, so results may not apply broadly. The drug may cause side effects or fail to show meaningful benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site 01
Rochester, Minnesota, 55905, United States
-
Investigational Site 02
Sofia, Bulgaria
-
Investigational Site 03
Melbourne, Australia
-
Investigational Site 04
Vienna, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.